Pancreatic Disorders & Therapy
Open Access

Paul Toomey

Publications

• Research Article
  Sulfonylureas (Not Metformin) Improve Survival for Patients with Diabetes and Resectable Pancreatic Adenocarcinoma
  Author(s): Paul Toomey, Anthony Teta, Krishen Patel, Kenneth Luberice, Sharona Ross and Alexander Rosemurgy Paul Toomey, Anthony Teta, Krishen Patel, Kenneth Luberice, Sharona Ross and Alexander Rosemurgy
  
  Objective: Patients with pancreatic adenocarcinoma have an increased propensity for diabetes. Recent studies suggest patients with diabetes and pancreatic adenocarcinoma treated with metformin have increased survival. This study was undertaken to determine if metformin use is associated with increased survival for patients with pancreatic adenocarcinoma. Methods: Patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma from 1991-2013 were included in this study. Survival was evaluated by Kaplan-Meier analysis. Median data are reported. Significance was accepted with 95% probability. Results: Out of 414 patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma, 132 (32%) was diabetic. Of diabetic patients, 35 (27%) were diet-controlled, 34 (26%) were treated with insulin alone, 18.. View More»
  DOI: 10.4172/2165-7092.S5-001

  Abstract PDF

Relevant Topics